1932

Abstract

The beginning of the twenty-first century was marked by the innovative use of pharmacochemical interventions, which have since expanded to include gene-based molecular therapies. For years, treatment has focused on tackling the pathophysiology of monogenic orphan diseases, and one of the first applications of these novel genome editing technologies was the treatment of rare inherited retinal dystrophies. In this review, we present recent, ongoing, and future gene therapy–based treatment trials for choroideremia, X-linked retinitis pigmentosa, Stargardt disease, and age-related macular degeneration. As these trials pave the way toward halting the progression of such devastating diseases, we will begin to see the exciting development of newer, cutting-edge strategies including base editing and prime editing, ushering in a new era of precision medicine.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-vision-100419-111701
2021-09-15
2024-06-24
Loading full text...

Full text loading...

/deliver/fulltext/vision/7/1/annurev-vision-100419-111701.html?itemId=/content/journals/10.1146/annurev-vision-100419-111701&mimeType=html&fmt=ahah

Literature Cited

  1. AGTC (Appl. Genet. Technol. Corp.) 2019. AGTC announces Stargardt disease as its second preclinical ophthalmology program and reports compelling preclinical data supporting the potential of its dual-vector technology Rep., AGTC Alachua, FL: https://agtc.com/agtc-announces-stargardt-disease-as-its-second-preclinical-ophthalmology-program-and-reports-compelling-preclinical-data-supporting-the-potential-of-its-dual-vector-technology/#:∼:text=5%2C%202019%20%E2%80%93%20Applied%20Genetic%20Technologies,second%20ophthalmology%20program%20in%20its
    [Google Scholar]
  2. AGTC (Appl. Genet. Technol. Corp.) 2020. AGTC reports positive six-month data from its ongoing Phase 1/2 clinical trial in X-linked retinitis pigmentosa. Globe Newswire Jan. 9, https://www.globenewswire.com/news-release/2020/01/09/1968341/0/en/AGTC-Reports-Positive-Six-Month-Data-from-its-Ongoing-Phase-1-2-Clinical-Trial-in-X-Linked-Retinitis-Pigmentosa.html
    [Google Scholar]
  3. Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A et al. 1997. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat. Genet. 15:236–46
    [Google Scholar]
  4. Ambati J, Fowler BJ. 2012. Mechanisms of age-related macular degeneration. Neuron 75:26–39
    [Google Scholar]
  5. Anderson WF, Fletcher JC. 1980. Gene therapy in human beings: When is it ethical to begin?. N. Engl. J. Med. 303:1293–97
    [Google Scholar]
  6. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW et al. 2019. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576:149–57
    [Google Scholar]
  7. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R et al. 2008. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358:2231–39
    [Google Scholar]
  8. Benhar I, London A, Schwartz M. 2012. The privileged immunity of immune privileged organs: the case of the eye. Front. Immunol. 3:296
    [Google Scholar]
  9. Birch DG, Locke KG, Wen Y, Locke KI, Hoffman DR, Hood DC. 2013. Spectral-domain optical coherence tomography measures of outer segment layer progression in patients with X-linked retinitis pigmentosa. JAMA Ophthalmol 131:1143–50
    [Google Scholar]
  10. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T et al. 1995. T lymphocyte-directed gene therapy for ADA SCID: initial trial results after 4 years. Science 270:475–80
    [Google Scholar]
  11. Broadgate S, Yu J, Downes SM, Halford S. 2017. Unravelling the genetics of inherited retinal dystrophies: past, present and future. Prog. Retin. Eye Res. 59:53–96
    [Google Scholar]
  12. Cai CX, Locke KG, Ramachandran R, Birch DG, Hood DC. 2014. A comparison of progressive loss of the ellipsoid zone (EZ) band in autosomal dominant and x-linked retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 55:7417–22
    [Google Scholar]
  13. Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S et al. 2017. Lentiviral vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) study. Hum. Gene Ther 28:99–111
    [Google Scholar]
  14. Can. Agency Drugs Technol. Health 2015a. Aflibercept (Eylea): Treatment of Neovascular (Wet) Age-Related Macular Degeneration (wAMD) Ottawa, ON, Can: Can. Agency Drugs Technol. Health
    [Google Scholar]
  15. Can. Agency Drugs Technol. Health 2015b. Ranibizumab (Lucentis): Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Ottawa, ON, Can: Can. Agency Drugs Technol. Health
    [Google Scholar]
  16. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–72
    [Google Scholar]
  17. Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C, Nanda A, Davies A et al. 2020. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat. Med. 26:354–59
    [Google Scholar]
  18. ClinicalTrials.gov 2011. Gene therapy for blindness caused by choroideremia Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT01461213
    [Google Scholar]
  19. ClinicalTrials.gov 2014. An open label clinical trial of retinal gene therapy for choroideremia Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02077361
    [Google Scholar]
  20. ClinicalTrials.gov 2015a. Choroideremia gene therapy clinical trial Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02553135
    [Google Scholar]
  21. ClinicalTrials.gov 2015b. REP1 gene replacement therapy for choroideremia (REGENERATE) Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02407678
    [Google Scholar]
  22. ClinicalTrials.gov 2015c. Safety and dose escalation study of AAV2-hCHM in subjects with CHM (choroideremia) gene mutations Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02341807
    [Google Scholar]
  23. ClinicalTrials.gov 2016. THOR—Tübingen Choroideremia Gene Therapy Trial (THOR) Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT02671539
    [Google Scholar]
  24. ClinicalTrials.gov 2017a. A clinical trial of retinal gene therapy for X-linked retinitis pigmentosa (XIRIUS) Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03116113
    [Google Scholar]
  25. ClinicalTrials.gov 2017b. Gene therapy for X-linked retinitis pigmentosa (XLRP) retinitis pigmentosa GTPase regulator (RPGR) Rep., Natl. Inst. Health Bethesda, MD: https://www.clinicaltrials.gov/ct2/show/NCT03252847
    [Google Scholar]
  26. ClinicalTrials.gov 2017c. Safety and efficacy of rAAV2tYF-GRK1-RPGR in subjects with X-linked retinitis pigmentosa caused by RPGR mutations Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03316560
    [Google Scholar]
  27. ClinicalTrials.gov 2017d. Safety and tolerability of RGX-314 gene therapy for neovascular AMD trial Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03066258
    [Google Scholar]
  28. ClinicalTrials.gov 2017e. Treatment of advanced dry age related macular degeneration with AAVCAGsCD59 Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03144999
    [Google Scholar]
  29. ClinicalTrials.gov 2018a. Efficacy and safety of BIIB111 for the treatment of choroideremia (STAR) Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03496012
    [Google Scholar]
  30. ClinicalTrials.gov 2018b. A safety study of retinal gene therapy for choroideremia with administration of BIIB111 (GEMINI) Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT03507686
    [Google Scholar]
  31. ClinicalTrials.gov 2020. Dose escalation study of intravitreal 4D-110 in patients with choroideremia Rep., Natl. Inst. Health Bethesda, MD: https://clinicaltrials.gov/ct2/show/NCT04483440
    [Google Scholar]
  32. Corum J, Zimmer C. 2021. How the Oxford-AstraZeneca vaccine works. The New York Times March 22. https://www.nytimes.com/interactive/2020/health/oxford-astrazeneca-covid-19-vaccine.html
    [Google Scholar]
  33. Cremers FP, van de Pol DJ, van Kerkhoff LP, Wieringa B, Ropers HH. 1990. Cloning of a gene that is rearranged in patients with choroideraemia. Nature 347:674–77
    [Google Scholar]
  34. Dimopoulos IS, Hoang SC, Radziwon A, Binczyk NM, Seabra MC et al. 2018. Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience. Am. J. Ophthalmol. 193:130–42
    [Google Scholar]
  35. Ding K, Shen J, Hafiz Z, Hackett SF, Silva RLE et al. 2019. AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression. J. Clin. Investig. 129:4901–11
    [Google Scholar]
  36. Duncan JL, Pierce EA, Laster AM, Daiger SP, Birch DG et al. 2018. Inherited retinal degenerations: current landscape and knowledge gaps. Transl. Vis. Sci. Technol. 7:6
    [Google Scholar]
  37. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. 2004. Gene therapy clinical trials worldwide 1989–2004: an overview. J. Gene Med. 6:597–602
    [Google Scholar]
  38. Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL et al. 2016. Visual acuity after retinal gene therapy for choroideremia. N. Engl. J. Med. 374:1996–98
    [Google Scholar]
  39. Fischer MD, McClements ME, Martinez-Fernandez de la Camara C, Bellingrath JS, Dauletbekov D et al. 2017. Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa. Mol. Ther. 25:1854–65
    [Google Scholar]
  40. Friedmann T. 1992. A brief history of gene therapy. Nat. Genet. 2:93–98
    [Google Scholar]
  41. Gasiunas G, Barrangou R, Horvath P, Siksnys V 2012. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. PNAS 109:E2579–86
    [Google Scholar]
  42. Gregory J, Birch DG, Kubota R. 2020. Randomized clinical trial evaluating the pharmacodynamics of emixustat in subjects with macular atrophy secondary to Stargardt disease. Investig. Ophthalmol. Vis. Sci. 61:3190
    [Google Scholar]
  43. Grishanin R, Vuillemenot B, Sharma P, Keravala A, Greengard J et al. 2019. Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration. Mol. Ther. 27:118–29
    [Google Scholar]
  44. Hariri AH, Velaga SB, Girach A, Ip MS, Le PV et al. 2017. Measurement and reproducibility of preserved ellipsoid zone area and preserved retinal pigment epithelium area in eyes with choroideremia. Am. J. Ophthalmol. 179:110–17
    [Google Scholar]
  45. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S et al. 2017. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet 390:50–61
    [Google Scholar]
  46. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. 2004. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am. J. Ophthalmol. 137:704–18
    [Google Scholar]
  47. Hood DC, Lazow MA, Locke KG, Greenstein VC, Birch DG. 2011. The transition zone between healthy and diseased retina in patients with retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 52:101–8
    [Google Scholar]
  48. Huang WC, Roman AJ, Cideciyan AV, Gewaily DY, Limberis MP et al. 2012. X-linked RP caused by RPGR mutations: natural history of the human disease and an RPGR-mutant rodent model. Investig. Ophthalmol. Vis. Sci. 53:2591
    [Google Scholar]
  49. Jacobson SG, Cideciyan AV, Sumaroka A, Aleman TS, Schwartz SB et al. 2006. Remodeling of the human retina in choroideremia: Rab escort protein 1 (REP-1) mutations. Investig. Ophthalmol. Vis. Sci. 47:4113–20
    [Google Scholar]
  50. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–21
    [Google Scholar]
  51. Johnson & Johnson 2020. Johnson & Johnson announces its first Phase 3 COVID-19 vaccine trial ENSEMBLE is fully enrolled Statement, Johnson & Johnson New Brunswick, NJ:
    [Google Scholar]
  52. Koch SF, Duong JK, Hsu CW, Tsai YT, Lin CS et al. 2017. Genetic rescue models refute nonautonomous rod cell death in retinitis pigmentosa. PNAS 114:5259–64
    [Google Scholar]
  53. Lam BL, Davis JL, Gregori NZ, MacLaren RE, Girach A et al. 2019. Choroideremia gene therapy Phase 2 clinical trial: 24-month results. Am. J. Ophthalmol. 197:65–73
    [Google Scholar]
  54. MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T et al. 2014. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383:1129–37
    [Google Scholar]
  55. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr., Mingozzi F et al. 2008. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358:2240–48
    [Google Scholar]
  56. McClements ME, Barnard AR, Singh MS, Charbel Issa P, Jiang Z et al. 2019. An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4˗/˗ mice. Hum. Gene Ther 30:590–600
    [Google Scholar]
  57. McKie R. 2000. Gene researchers face crisis as man's saviour turns killer. The Guardian Jan. 1. https://www.theguardian.com/science/2000/jan/02/genetics.medicaladvicefortravellers
    [Google Scholar]
  58. Michaelides M. 2020. AAV5-RPGR gene therapy for RPGR-associated X-linked retinitis pigmentosa: 12-month results from a Phase 1/2 clinical trial Paper presented at the American Association of Ophthalmology Virtual Meeting, Nov. 13
    [Google Scholar]
  59. Mukherjee N, Schuman S. 2014. Diagnosis and management of Stargardt disease. EyeNet Magazine Dec. https://www.aao.org/eyenet/article/diagnosis-management-of-stargardt-disease
    [Google Scholar]
  60. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. 2008. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 27:331–71
    [Google Scholar]
  61. Pennington KL, DeAngelis MM. 2016. Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors. Eye Vis 3:34
    [Google Scholar]
  62. PipelineReview.com 2020. Stargazer Pharmaceuticals, Inc. announces $57 million Series A financing and initiation of a Phase 2a clinical study of STG-001 in Stargardt disease patients. PipelineReview Nov. 10. https://pipelinereview.com/index.php/2020111076474/Small-Molecules/Stargazer-Pharmaceuticals-Inc.-Announces-$57-Million-Series-A-Financing-and-Initiation-of-a-Phase-2a-Clinical-Study-of-STG-001-in-Stargardt-Disease-Patients.html
    [Google Scholar]
  63. Ramachandran R, Zhou L, Locke KG, Birch DG, Hood DC. 2013. A comparison of methods for tracking progression in X-linked retinitis pigmentosa using frequency domain OCT. Transl. Vis. Sci. Technol. 2:5
    [Google Scholar]
  64. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A et al. 2003. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80:148–58
    [Google Scholar]
  65. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF et al. 2017. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390:849–60
    [Google Scholar]
  66. Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. 2007. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Investig. Ophthalmol. Vis. Sci. 48:1298–304
    [Google Scholar]
  67. Scholl HP, Tsang SH, Kay CN, Connor TB, Gorin MB et al. 2019. Stargardt disease ALK-001 phase 2 clinical trial: 12-month interim data. Investig. Ophthalmol. Vis. Sci. 60:1336
    [Google Scholar]
  68. Seabra MC, Brown MS, Goldstein JL. 1993. Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science 259:377–81
    [Google Scholar]
  69. Simunovic MP, Jolly JK, Xue K, Edwards TL, Groppe M et al. 2016. The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype. Investig. Ophthalmol. Vis. Sci. 57:6033–39
    [Google Scholar]
  70. Sparrow JR, Marsiglia M, Allikmets R, Tsang S, Lee W et al. 2015. Flecks in recessive Stargardt disease: short-wavelength autofluorescence, near-infrared autofluorescence, and optical coherence tomography. Investig. Ophthalmol. Vis. Sci 56:5029–39
    [Google Scholar]
  71. Tanna P, Strauss RW, Fujinami K, Michaelides M. 2017. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br. J. Ophthalmol. 101:25–30
    [Google Scholar]
  72. Tee JJL, Carroll J, Webster AR, Michaelides M. 2017. Quantitative analysis of retinal structure using spectral-domain optical coherence tomography in RPGR-associated retinopathy. Am. J. Ophthalmol. 178:18–26
    [Google Scholar]
  73. Tee JJL, Yang Y, Kalitzeos A, Webster A, Bainbridge J, Michaelides M. 2019. Natural history study of retinal structure, progression, and symmetry using ellipzoid zone metrics in RPGR-associated retinopathy. Am. J. Ophthalmol. 198:111–23
    [Google Scholar]
  74. Tsai YT, Wu WH, Lee TT, Wu WP, Xu CL et al. 2018. Clustered regularly interspaced short palindromic repeats-based genome surgery for the treatment of autosomal dominant retinitis pigmentosa. Ophthalmology 125:1421–30
    [Google Scholar]
  75. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM et al. 2020. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111
    [Google Scholar]
  76. Wert KJ, Lin JH, Tsang SH. 2014. General pathophysiology in retinal degeneration. Dev. Ophthalmol. 53:33–43
    [Google Scholar]
  77. Xue K, Groppe M, Salvetti AP, MacLaren RE. 2017. Technique of retinal gene therapy: delivery of viral vector into the subretinal space. Eye 31:1308–16
    [Google Scholar]
  78. Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP et al. 2018. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat. Med. 24:1507–12
    [Google Scholar]
  79. Zheng A, Li Y, Tsang SH. 2015. Personalized therapeutic strategies for patients with retinitis pigmentosa. Expert Opin. Biol. Ther. 15:391–402
    [Google Scholar]
/content/journals/10.1146/annurev-vision-100419-111701
Loading
/content/journals/10.1146/annurev-vision-100419-111701
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error